Canada's Drug Agency
L'Agence des médicaments du Canada

Patient Engagement at Canada's Drug Agency

Formulary Management Expert Committee

Project Details

Project:	Dabrafenib-trametinib for BRAF V600E mutant anaplastic thyroid cancer
Patient Profile:	Patients with BRAF V600E mutant anaplastic thyroid cancer with experience with Dabrafenib-trametinib. If no experience with Dabrafenib-trametinib, experience with other treatments such as Paclitaxel-carboplatin, Docetaxel-doxorubicin, Paclitaxel, or Doxorubicin would also be suitable.
Project Type:	FMEC presentation & Dialogue with Committee
Timeframe:	December to April 2025. Presentation on March 20, 2025.
Activities:	Initial introductory call (30 mins) Preparing presentation notes (45 mins) Committee meeting presentation and Q&A (15-30 mins) (with optional debrief call if requested)
Method:	Zoom or in person
Compensation:	$100 Gift Card
Forms:	Consent, Non-Disclosure, Conflict-of-Interest & Honorarium forms
Privacy:	You can be thanked by name or remain anonymous
Output:	A summary of your presentation and Q&A answers will be shared with you for your approval A report will be published online and available for distribution.
Contact:	Sam Sutherland
Role:	Engagement Officer
Email:	sam.sutherland@cadth.ca

About CDA-AMC

Canada's Drug Agency is a not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies, including drugs, diagnostic tests, medical, dental, and surgical devices, and procedures. In addition to evidence, we also provide advice, recommendations, and tools.

We do not make decisions about funding, nor do we conduct clinical trials. We gather, review, appraise, and summarize the available evidence for decision-makers. Projects come to us from provincial, territorial or federal jurisdictions, health authorities, hospitals, or pharmaceutical companies, or we initiate them ourselves.

For more information about CDA-AMC, visit our website or read our Strategic Plan.

How the Drug Funding Process Works

Canada's Drug Agency is funded by federal, provincial, and territorial governments, except Quebec (which has its own health technology assessment body, INESSS), and receives fees from pharmaceutical companies.

Medications are first approved for use in Canada by Health Canada and come to CDA-AMC (and INESSS) for a Reimbursement Review. CDA-AMC conducts their review, and the relevant expert committee issues a recommendation as to whether a drug should be reimbursed by provincial and territorial formularies (Drug Plans).



When drugs are recommended to be reimbursed, the pan-Canadian Pharmaceutical Alliance (pCPA) negotiates the pricing with pharmaceutical companies. After negotiations, the publicly funded drug plans determine whether to include those drugs on their public drug plan.

Formulary Management Expert Committee (FMEC)

The pilot Formulary Management Expert Committee provides recommendations to CDA-AMC's non-sponsored single drug reviews, streamlined drug class reviews, and therapeutic reviews. The expert committee includes a patient expert member who has equal voting rights to other expert members.

A person with experience (patient, family, caregiver) of the condition and medication(s) under review is invited to present directly to the expert committee, and to answer questions from the committee members. Their insights and perspectives help us understand the disease area, and the Canadian healthcare landscape more comprehensively for those living with the condition. A summary of the patient contributor's presentation is included in the final recommendation as well as they are thanked by name for their contribution.

An optional debrief meeting is available after the engagement session to offer support and discuss the engagement. This is completely up to the patient and not a requirement.